Ensysce Biosciences Financials
ENSC Stock | USD 0.59 0.07 10.61% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 0.65 | 0.6867 |
|
|
Investors should never underestimate Ensysce Biosciences' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Ensysce Biosciences' cash flow, debt, and profitability to make informed and accurate decisions about investing in Ensysce Biosciences.
Cash And Equivalents |
|
Ensysce | Select Account or Indicator |
Understanding current and past Ensysce Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Ensysce Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Ensysce Biosciences' assets may result in an increase in income on the income statement.
Please note, the presentation of Ensysce Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ensysce Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ensysce Biosciences' management manipulating its earnings.
Ensysce Biosciences Stock Summary
Ensysce Biosciences competes with ZyVersa Therapeutics, Sonnet Biotherapeutics, Zura Bio, Phio Pharmaceuticals, and Transcode Therapeutics. Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614 PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse and PF26810, an extended-release prodrug of methadone for opioid use disorder. Ensysce Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US2936021086 |
CUSIP | 52539T107 293602108 293602405 293602207 |
Location | California; U.S.A |
Business Address | 7946 Ivanhoe Avenue, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.ensysce.com |
Phone | 858 263 4196 |
Currency | USD - US Dollar |
Ensysce Biosciences Key Financial Ratios
Return On Equity | -4.28 | ||||
Operating Margin | (10.76) % | ||||
Price To Sales | 8.93 X | ||||
Revenue | 2.23 M | ||||
Gross Profit | (1.16 M) |
Ensysce Biosciences Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 196.5M | 351.8K | 16.4M | 5.9M | 2.7M | 2.6M | |
Retained Earnings | 2.5M | (56.0M) | (85.8M) | (110.9M) | (121.6M) | (115.5M) | |
Cash | 1.1M | 194.2K | 12.3M | 3.1M | 1.1M | 1.1M | |
Other Assets | 5K | 3.8K | 754.8K | 585.9K | 527.3K | 500.9K | |
Long Term Debt Total | 566.3K | 791.3K | 4.4M | 140.2K | 161.2K | 153.1K | |
Capital Surpluse | 2.9M | 2.5M | 78.0M | 107.2M | 123.3M | 129.5M | |
Total Liab | 10.3M | 7.0M | 24.6M | 9.9M | 3.4M | 3.2M | |
Total Current Assets | 1.2M | 347.9K | 15.7M | 5.3M | 2.3M | 2.2M | |
Short Term Debt | 2.6M | 4.3M | 12.7M | 4.3M | 854.7K | 812.0K | |
Common Stock | 181.2M | 1.6K | 2.5K | 642.0 | 315.0 | 299.25 | |
Other Current Liab | 2.8M | 856.0K | 3.4M | 2.3M | 542.3K | 515.1K | |
Net Debt | (494.9K) | 4.1M | 483.4K | 1.3M | (268.9K) | (255.5K) | |
Accounts Payable | 540.8K | 1.7M | 301.1K | 2.9M | 1.9M | 1.4M | |
Other Current Assets | 138.6K | 153.7K | 3.4M | 2.2M | 1.1M | 1.3M |
Ensysce Biosciences Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Income | 4.2M | 939.7K | 622K | 109.5K | 98.6K | 93.6K | |
Total Revenue | 1.8M | 3.9M | 3.5M | 2.5M | 2.2M | 2.2M | |
Operating Income | (3.3M) | (1.6M) | (19.9M) | (24.2M) | (10.7M) | (11.3M) | |
Income Before Tax | 921.2K | (160.9K) | (29.1M) | (24.2M) | (10.6M) | (11.2M) | |
Net Income | 1.5M | (938.7K) | (29.1M) | (25.0M) | (10.6M) | (11.1M) | |
Gross Profit | (3.3M) | 2.6M | 3.5M | (17.3M) | (5.4M) | (5.6M) | |
Ebit | (3.3M) | (1.6M) | (19.9M) | (24.2M) | (10.7M) | (11.3M) | |
Ebitda | (3.3M) | (1.6M) | (19.9M) | (24.2M) | (10.7M) | (11.3M) | |
Cost Of Revenue | 3.3M | 1.4M | 151.0 | 19.8M | 7.6M | 6.2M | |
Income Tax Expense | (555.2K) | 777.9K | (151.0) | 753.9K | (264.0) | (250.8) |
Ensysce Biosciences Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change In Cash | (597.2K) | (147.3K) | 12.1M | (9.1M) | (2.0M) | (1.9M) | |
Free Cash Flow | 11.0M | (1.2M) | (8.2M) | (17.9M) | (10.8M) | (10.2M) | |
Other Non Cash Items | 8.2M | 997.5K | 7.5M | (233.4K) | (411.9K) | (391.3K) | |
Net Income | 366.0K | (160.9K) | (29.1M) | (24.2M) | (10.6M) | (11.2M) | |
End Period Cash Flow | 1.1M | 194.2K | 12.3M | 3.1M | 1.1M | 1.1M |
Ensysce Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ensysce Biosciences's current stock value. Our valuation model uses many indicators to compare Ensysce Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ensysce Biosciences competition to find correlations between indicators driving Ensysce Biosciences's intrinsic value. More Info.Ensysce Biosciences is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Ensysce Biosciences' Return On Equity is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ensysce Biosciences' earnings, one of the primary drivers of an investment's value.Ensysce Biosciences Systematic Risk
Ensysce Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Ensysce Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Ensysce Biosciences correlated with the market. If Beta is less than 0 Ensysce Biosciences generally moves in the opposite direction as compared to the market. If Ensysce Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Ensysce Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Ensysce Biosciences is generally in the same direction as the market. If Beta > 1 Ensysce Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Ensysce Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ensysce Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Ensysce Biosciences growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Ensysce Biosciences November 21, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Ensysce Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Ensysce Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Ensysce Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Ensysce Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ensysce Biosciences's daily price indicators and compare them against related drivers.
Downside Deviation | 11.59 | |||
Information Ratio | 0.1009 | |||
Maximum Drawdown | 183.07 | |||
Value At Risk | (17.24) | |||
Potential Upside | 27.27 |
Complementary Tools for Ensysce Stock analysis
When running Ensysce Biosciences' price analysis, check to measure Ensysce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ensysce Biosciences is operating at the current time. Most of Ensysce Biosciences' value examination focuses on studying past and present price action to predict the probability of Ensysce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ensysce Biosciences' price. Additionally, you may evaluate how the addition of Ensysce Biosciences to your portfolios can decrease your overall portfolio volatility.
Money Managers Screen money managers from public funds and ETFs managed around the world | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
CEOs Directory Screen CEOs from public companies around the world | |
Stocks Directory Find actively traded stocks across global markets | |
Transaction History View history of all your transactions and understand their impact on performance | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |